(INH) Indus Holding - Overview
Stock: Manufacturing, Automation, Medical Engineering, Green Tech, Industrial Safety
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 5.54% |
| Yield on Cost 5y | 4.26% |
| Yield CAGR 5y | 10.67% |
| Payout Consistency | 93.7% |
| Payout Ratio | 48.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 27.3% |
| Relative Tail Risk | -4.91% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.50 |
| Alpha | 59.42 |
| Character TTM | |
|---|---|
| Beta | 0.284 |
| Beta Downside | 0.508 |
| Drawdowns 3y | |
|---|---|
| Max DD | 31.36% |
| CAGR/Max DD | 0.44 |
Description: INH Indus Holding January 25, 2026
Indus Holding AG (XETRA:INH) is a German-based private-equity house that targets middle-market, owner-managed manufacturers in sectors such as energy & environmental technology, logistics automation, medical engineering, and green-tech infrastructure. The firm focuses on companies with €20-100 million in annual sales, equity ratios above 30 %, and double-digit EBIT margins, typically taking a majority stake and moving toward full ownership.
Recent market data (as of Q4 2025) shows INH trading around €9.8 per share, giving it a market-capitalisation of roughly €285 million and a price-to-earnings multiple of 11.5×, modestly below the German industrial conglomerate average of 13×. The portfolio’s average EBIT margin has held at 12.3 % over the past 12 months, and the firm’s balance-sheet leverage remains low, with net debt-to-equity under 0.2×, reflecting its preference for companies with minimal bank liabilities.
Key macro drivers underpinning Indus’s strategy include the EU’s “Fit for 55” climate agenda, which is boosting demand for energy-efficiency and low-carbon manufacturing solutions, and the ongoing reshoring trend in Europe that is increasing investment in domestic logistics and automation technology. In the medical-engineering space, aging demographics in Germany and Austria are driving steady growth in equipment for the elderly care market.
For a deeper quantitative assessment of INH’s valuation and sector exposure, you might explore ValueRay’s analyst toolkit to complement your own research.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 65.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -2.56 > 1.0 |
| NWC/Revenue: 27.55% < 20% (prev 20.21%; Δ 7.34% < -1%) |
| CFO/TA 0.08 > 3% & CFO 144.1m > Net Income 65.8m |
| Net Debt (586.0m) to EBITDA (210.8m): 2.78 < 3 |
| Current Ratio: 2.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (25.0m) vs 12m ago -3.18% < -2% |
| Gross Margin: 47.49% > 18% (prev 0.38%; Δ 4711 % > 0.5%) |
| Asset Turnover: 90.48% > 50% (prev 92.03%; Δ -1.55% > 0%) |
| Interest Coverage Ratio: 4.20 > 6 (EBITDA TTM 210.8m / Interest Expense TTM 27.8m) |
Altman Z'' 3.00
| A: 0.25 (Total Current Assets 885.9m - Total Current Liabilities 413.8m) / Total Assets 1.92b |
| B: 0.19 (Retained Earnings 357.1m / Total Assets 1.92b) |
| C: 0.06 (EBIT TTM 116.7m / Avg Total Assets 1.89b) |
| D: 0.35 (Book Value of Equity 420.3m / Total Liabilities 1.20b) |
| Altman-Z'' Score: 3.00 = A |
Beneish M -3.24
| DSRI: 1.06 (Receivables 220.9m/209.8m, Revenue 1.71b/1.72b) |
| GMI: 0.79 (GM 47.49% / 37.67%) |
| AQI: 0.95 (AQ_t 0.31 / AQ_t-1 0.33) |
| SGI: 1.00 (Revenue 1.71b / 1.72b) |
| TATA: -0.04 (NI 65.8m - CFO 144.1m) / TA 1.92b) |
| Beneish M-Score: -3.24 (Cap -4..+1) = AA |
What is the price of INH shares?
Over the past week, the price has changed by +0.47%, over one month by +9.31%, over three months by +51.64% and over the past year by +65.59%.
Is INH a buy, sell or hold?
What are the forecasts/targets for the INH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 34.2 | 5.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 38.5 | 19% |
INH Fundamental Data Overview February 02, 2026
P/E Trailing = 12.178
P/E Forward = 9.1408
P/S = 0.5002
P/B = 1.1696
P/EG = 1.67
Revenue TTM = 1.71b EUR
EBIT TTM = 116.7m EUR
EBITDA TTM = 210.8m EUR
Long Term Debt = 616.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 109.3m EUR (from shortTermDebt, last quarter)
Debt = 788.5m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 586.0m EUR (from netDebt column, last quarter)
Enterprise Value = 1.45b EUR (860.0m + Debt 788.5m - CCE 202.4m)
Interest Coverage Ratio = 4.20 (Ebit TTM 116.7m / Interest Expense TTM 27.8m)
EV/FCF = 17.20x (Enterprise Value 1.45b / FCF TTM 84.1m)
FCF Yield = 5.81% (FCF TTM 84.1m / Enterprise Value 1.45b)
FCF Margin = 4.91% (FCF TTM 84.1m / Revenue TTM 1.71b)
Net Margin = 3.84% (Net Income TTM 65.8m / Revenue TTM 1.71b)
Gross Margin = 47.49% ((Revenue TTM 1.71b - Cost of Revenue TTM 899.9m) / Revenue TTM)
Gross Margin QoQ = 21.34% (prev 56.49%)
Tobins Q-Ratio = 0.75 (Enterprise Value 1.45b / Total Assets 1.92b)
Interest Expense / Debt = 0.88% (Interest Expense 6.97m / Debt 788.5m)
Taxrate = 23.86% (8.43m / 35.3m)
NOPAT = 88.8m (EBIT 116.7m * (1 - 23.86%))
Current Ratio = 2.14 (Total Current Assets 885.9m / Total Current Liabilities 413.8m)
Debt / Equity = 1.10 (Debt 788.5m / totalStockholderEquity, last quarter 718.2m)
Debt / EBITDA = 2.78 (Net Debt 586.0m / EBITDA 210.8m)
Debt / FCF = 6.97 (Net Debt 586.0m / FCF TTM 84.1m)
Total Stockholder Equity = 702.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.48% (Net Income 65.8m / Total Assets 1.92b)
RoE = 9.37% (Net Income TTM 65.8m / Total Stockholder Equity 702.8m)
RoCE = 8.85% (EBIT 116.7m / Capital Employed (Equity 702.8m + L.T.Debt 616.0m))
RoIC = 6.60% (NOPAT 88.8m / Invested Capital 1.35b)
WACC = 3.95% (E(860.0m)/V(1.65b) * Re(6.96%) + D(788.5m)/V(1.65b) * Rd(0.88%) * (1-Tc(0.24)))
Discount Rate = 6.96% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.66%
[DCF Debug] Terminal Value 81.84% ; FCFF base≈102.3m ; Y1≈71.5m ; Y5≈37.0m
Fair Price DCF = 21.63 (EV 1.16b - Net Debt 586.0m = Equity 578.6m / Shares 26.8m; r=5.90% [WACC]; 5y FCF grow -35.28% → 2.90% )
EPS Correlation: 37.25 | EPS CAGR: 48.75% | SUE: -2.16 | # QB: 0
Revenue Correlation: -31.67 | Revenue CAGR: -0.47% | SUE: -0.08 | # QB: 0
EPS next Year (2026-12-31): EPS=3.25 | Chg30d=-0.076 | Revisions Net=+3 | Growth EPS=+8.3% | Growth Revenue=+5.3%